Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Skin Residency of GSK2894512 in Healthy Volunteers
NCT02411162Phase 1Completed
- Sponsor
- GSK
- Start
- Jul 2015
- Primary completion
- Sep 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tapinarof in atopic dermatitis (AD), sponsored by GSK. Primary endpoint: Residence time in skin following topical application at Day 15. Started Jul 2015; status: completed.
02
Drugs
tapinarof
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT02411162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02411162.